University of Miami

Tetra Discovery Partners, LLC

W Dalton Dietrich

Mark E Gurney

Michael Y Wang

Helen M Bramlett

Robert W Keane

Juan Pablo De Rivero Vaccari

Roberta Brambilla

Coleen M Atkins

David J Adaikkalasamy

M Ross Bullock

Allan Levi

Stephanie Adamczak

The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.

Methods and compositions for treating virus-associated inflammation

The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.

Methods for treating lung inflammation with an anti-ASC antibody

Methods and compositions for treating multiple sclerosis

Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage. Further, in a rodent thromboembolic stroke model, neutralization of NLRP1 resulted in reduced histopathological damage in mice and reduced cytokine activation, suggesting that the inflammasome complex forms in the brain after stroke and is a therapeutic target for reducing the detrimental consequences of post-stroke inflammation.

Methods of modulating inflammasome activity to treat inflammatory conditions

Provided herein are methods of improving cognitive ability or memory in a subject that has suffered a brain injury or spinal cord injury by administering a selective PDE4 B inhibitor.

Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury

Modulating inflammasome activity and inflammation in the central nervous system

Growing community of inventors

Miami, FL, United States of America

W Dalton Dietrich